CD9

Across TCGA pan-cancer cohorts, CD9 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CD9 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CD9 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CD9 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LSCC show a favorable association.

PDAC, UCEC, and CCRCC are the cancer types where CD9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	IV	0.214	0.785	.006	23	view →
UCEC	DFS	Quartile	II,III,IV	1.000	0.481	.018	20	view →
CCRCC	DFS	Tertile	IV	0.198	0.887	.024	16	view →
LSCC	DFS	Tertile	III,IV	1.000	0.500	.009	11	view →
GBM	DFS	Quartile	All	0.199	0.494	.036	4	view →
HNSC	OS	Median	All	0.627	0.795	.017	3	view →
LUAD	OS	Quartile	III,IV	0.821	0.396	.008	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CD9–PDAC (DFS)

Open the PDAC breakdown →